+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Mediated Tumor Killing Assays Service Market - Global Forecast 2026-2032- Product Image
Immune Mediated Tumor Killing Assays Service Market - Global Forecast 2026-2032- Product Image
Sale

Immune Mediated Tumor Killing Assays Service Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6278619
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Immune-Mediated Tumor-Killing Assays: Executive Summary

Immune-mediated tumor-killing assays service providers support oncology research by measuring how immune cells, antibodies, cellular therapies, and combination treatments affect tumor cells. Core applications include cytotoxicity, target engagement, immune-cell activation, resistance assessment, and preclinical translational studies. Demand is shaped by the expansion of immuno-oncology pipelines, increasing use of patient-derived models, and the need for reproducible evidence across discovery and development workflows.

From Endpoint Testing to Translational Immune Profiling

The service landscape is shifting from simple viability endpoints toward integrated assay designs that capture tumor-cell death, immune-cell function, cytokine release, phenotypic changes, and mechanism of action. Multiplex readouts, three-dimensional cultures, organoid systems, and co-culture models are helping researchers address biological complexity that is not represented by conventional two-dimensional assays. Standardization, assay qualification, controls, and cross-platform comparability are becoming increasingly important as results move from exploratory research into regulated development programs.

Artificial Intelligence Strengthens Assay Design and Interpretation

Artificial intelligence is contributing to experimental planning, image analysis, cell classification, anomaly detection, and interpretation of high-dimensional assay outputs. Machine-learning workflows can help identify response patterns across immune-cell states, tumor characteristics, treatment conditions, and time points, while computer vision can improve segmentation and phenotypic scoring. Adoption remains dependent on well-annotated datasets, transparent validation, appropriate controls, data governance, and expert review; AI should therefore complement rather than replace biological and statistical judgment.

Regional Patterns: Infrastructure, Regulation, and Translational Demand

North America combines strong immuno-oncology activity with established contract research, clinical-development, and advanced imaging capabilities. Europe benefits from sophisticated academic networks and regulatory attention to reproducibility, while Asia-Pacific is expanding its biopharma, translational research, and laboratory service infrastructure. Latin America is building capacity through academic and clinical partnerships, with access and standardization remaining important considerations. The Middle East is strengthening biomedical research ecosystems around specialized institutions, and Africa presents opportunities linked to locally relevant translational research, although infrastructure, funding continuity, and specialized technical capacity vary widely across markets.

Group-Level Insights Across Strategic Economic and Security Blocs

ASEAN’s increasingly connected biomedical ecosystem supports cross-border collaboration, but service access and laboratory capabilities differ among members. BRICS economies contribute substantial scientific and clinical diversity, alongside varied regulatory systems and data infrastructures. The European Union emphasizes collaborative research, harmonization, and data protection. G7 countries generally offer mature assay-development environments and deep biopharma expertise. GCC states are investing in biomedical and precision-health capabilities, while NATO members provide a broad network of research institutions and technical infrastructure, with priorities shaped by national health systems and security considerations.

Country-Level Signals in Assay Capability and Application

The United States and Canada have broad capabilities in translational immuno-oncology, advanced cell analysis, and outsourced research. The United Kingdom, Germany, France, Italy, and Spain combine university, hospital, and biotechnology expertise, with European data and regulatory requirements influencing service design. China, Japan, and South Korea are expanding sophisticated oncology research and technology platforms. Australia supports strong academic and clinical research networks. India is developing cost-conscious, technically capable research services. Brazil and Mexico are strengthening translational ecosystems, while Russia’s research environment reflects distinct institutional, regulatory, and collaboration conditions. Across all countries, local validation, sample logistics, biosafety, and data-transfer requirements affect project execution.

Priorities for Leaders Building Reliable Assay Programs

Industry leaders should select platforms according to the biological question rather than relying on a single universal endpoint. Programs should combine orthogonal measurements, appropriate positive and negative controls, relevant tumor and immune-cell models, and predefined acceptance criteria. Service partners should be evaluated for scientific expertise, sample handling, documentation, data integrity, turnaround discipline, and capacity to adapt methods without compromising comparability. Leaders can also improve resilience by qualifying alternative workflows, protecting sensitive patient and proprietary data, and using AI only within validated analytical pipelines with human oversight.

Methodology: Evidence-Based Synthesis of the Service Landscape

This executive summary uses the defined market scope of immune-mediated tumor-killing assays service and synthesizes established evidence themes from oncology research practice, assay-development principles, translational science, laboratory operations, and regional biomedical infrastructure. Findings are organized by technology evolution, AI applications, geography, economic and institutional groupings, and country context. No market estimates, shares, forecasts, or company-specific claims are used. Because capabilities vary by institution and project, regional and country observations are qualitative and should be validated against current regulatory, technical, and procurement conditions before investment decisions.

Conclusion: Reproducibility and Biological Relevance Will Differentiate Services

Immune-mediated tumor-killing assays services are becoming more integrated, data-rich, and translationally focused. The strongest programs will connect biologically relevant models with multiplex measurements, rigorous controls, robust analytics, and clear documentation. Regional capability is uneven but expanding through academic, clinical, and biopharma collaboration. Leaders that prioritize reproducibility, model relevance, validated AI support, and flexible geographic execution will be better positioned to generate decision-ready evidence for immuno-oncology research.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immune Mediated Tumor Killing Assays Service Market, by Assay Type
7.1. Introduction
7.2. Antibody-Dependent Cellular Cytotoxicity (ADCC)
7.3. Antibody-Dependent Cellular Phagocytosis (ADCP)
7.4. Apoptosis And Cell Death Assays
7.5. CAR-T Cell Cytotoxicity
7.5.1. Allogeneic CAR-T
7.5.2. Autologous CAR-T
7.6. Complement-Dependent Cytotoxicity (CDC)
7.7. NK Cell Cytotoxicity
7.8. T Cell Mediated Killing
8. Immune Mediated Tumor Killing Assays Service Market, by Detection Method
8.1. Introduction
8.2. ELISA And Cytokine Profiling
8.3. Flow Cytometry
8.4. Fluorescence Imaging
8.5. High Content Imaging
8.6. Impedance-Based Assay
8.7. LDH Release Assay
8.8. Luminescence Assays
9. Immune Mediated Tumor Killing Assays Service Market, by Sample Type
9.1. Introduction
9.2. Engineered Reporter Cell Lines
9.3. Established Tumor Cell Lines
9.4. Ex Vivo Tumor Slices
9.5. Patient Derived Tumor Cells
9.6. Peripheral Blood Mononuclear Cells (PBMCs)
9.7. Tumor Organoids And Spheroids
10. Immune Mediated Tumor Killing Assays Service Market, by Assay Format
10.1. Introduction
10.2. 2D Monolayer Assays
10.3. 3D Co Culture Assays
10.3.1. Hanging Drop Spheroids
10.3.2. Matrix Embedded Organoids
10.4. Ex Vivo Tissue Slice Assays
10.5. Live Cell High Content Imaging Assays
10.6. Microfluidic Organ On Chip
11. Immune Mediated Tumor Killing Assays Service Market, by Service Model
11.1. Introduction
11.2. Fully Custom Assay Development
11.3. GLP Compliant Studies
11.4. Integrated Discovery Services
11.5. Project Based Contract Research
11.6. Standardized Assay Panels
12. Immune Mediated Tumor Killing Assays Service Market, by End User
12.1. Introduction
12.2. Academic And Research Institutes
12.3. Biotechnology Companies
12.4. Contract Research Organizations
12.5. Diagnostic And Companion Diagnostic Developers
12.6. Hospitals And Clinical Laboratories
12.7. Pharmaceutical Companies
13. Immune Mediated Tumor Killing Assays Service Market, by Therapeutic Application
13.1. Introduction
13.2. Bispecifics And BiTEs
13.3. Cell Therapies (CAR-T, TCR, CAR-NK)
13.4. Checkpoint Modulators
13.5. Monoclonal Antibodies
13.6. Vaccines And Immune Modulators
14. Immune Mediated Tumor Killing Assays Service Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Immune Mediated Tumor Killing Assays Service Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Immune Mediated Tumor Killing Assays Service Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Agilent Technologies, Inc.
18.2. Bio-Rad Laboratories, Inc.
18.3. BOC Sciences, Inc.
18.4. Charles River Laboratories, Inc.
18.5. Creative Biolabs, Inc.
18.6. Crown Bioscience, Inc.
18.7. EPO Berlin-Buch GmbH
18.8. Eurofins DiscoverX, LLC
18.9. Explicyte Immunology, Inc.
18.10. InnoSer B.V.
18.11. Nexus BioQuest LLC
18.12. Promega Corporation
18.13. Revvity, Inc.
18.14. Sartorius AG
18.15. WuXi AppTec Co., Ltd.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immune Mediated Tumor Killing Assays Service Market, Years Considered for the Study
FIGURE 2. Global Immune Mediated Tumor Killing Assays Service Market, Research Design
FIGURE 3. Global Immune Mediated Tumor Killing Assays Service Market, Research Framework
FIGURE 4. Global Immune Mediated Tumor Killing Assays Service Market, Data Triangulation
FIGURE 5. Global Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2025 vs 2032 (%)
FIGURE 7. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2025 vs 2032 (%)
FIGURE 9. Global Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2025 vs 2032 (%)
FIGURE 11. Global Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2025 vs 2032 (%)
FIGURE 13. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2025 vs 2032 (%)
FIGURE 15. Global Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 19. Global Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Immune Mediated Tumor Killing Assays Service Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Immune Mediated Tumor Killing Assays Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Immune Mediated Tumor Killing Assays Service Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immune Mediated Tumor Killing Assays Service Market Segmentation & Coverage
TABLE 2. Global Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 4. Global Antibody-Dependent Cellular Cytotoxicity (ADCC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antibody-Dependent Cellular Cytotoxicity (ADCC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antibody-Dependent Cellular Cytotoxicity (ADCC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Antibody-Dependent Cellular Phagocytosis (ADCP) Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Antibody-Dependent Cellular Phagocytosis (ADCP) Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Antibody-Dependent Cellular Phagocytosis (ADCP) Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Apoptosis And Cell Death Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Apoptosis And Cell Death Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Apoptosis And Cell Death Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global CAR-T Cell Cytotoxicity Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global CAR-T Cell Cytotoxicity Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global CAR-T Cell Cytotoxicity Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Allogeneic CAR-T Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Allogeneic CAR-T Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Allogeneic CAR-T Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Autologous CAR-T Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Autologous CAR-T Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Autologous CAR-T Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Complement-Dependent Cytotoxicity (CDC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Complement-Dependent Cytotoxicity (CDC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Complement-Dependent Cytotoxicity (CDC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global NK Cell Cytotoxicity Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global NK Cell Cytotoxicity Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global NK Cell Cytotoxicity Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global T Cell Mediated Killing Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global T Cell Mediated Killing Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global T Cell Mediated Killing Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 32. Global ELISA And Cytokine Profiling Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global ELISA And Cytokine Profiling Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global ELISA And Cytokine Profiling Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Flow Cytometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Flow Cytometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Flow Cytometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Fluorescence Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Fluorescence Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Fluorescence Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global High Content Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global High Content Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global High Content Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Impedance-Based Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Impedance-Based Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Impedance-Based Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global LDH Release Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global LDH Release Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global LDH Release Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Luminescence Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Luminescence Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Luminescence Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 54. Global Engineered Reporter Cell Lines Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Engineered Reporter Cell Lines Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Engineered Reporter Cell Lines Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Established Tumor Cell Lines Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Established Tumor Cell Lines Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Established Tumor Cell Lines Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Ex Vivo Tumor Slices Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Ex Vivo Tumor Slices Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Ex Vivo Tumor Slices Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Patient Derived Tumor Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Patient Derived Tumor Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Patient Derived Tumor Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Peripheral Blood Mononuclear Cells (PBMCs) Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Peripheral Blood Mononuclear Cells (PBMCs) Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Peripheral Blood Mononuclear Cells (PBMCs) Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Tumor Organoids And Spheroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Tumor Organoids And Spheroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Tumor Organoids And Spheroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 73. Global 2D Monolayer Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global 2D Monolayer Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global 2D Monolayer Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global 3D Co Culture Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global 3D Co Culture Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global 3D Co Culture Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Hanging Drop Spheroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Hanging Drop Spheroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Hanging Drop Spheroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Matrix Embedded Organoids Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Matrix Embedded Organoids Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Matrix Embedded Organoids Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Ex Vivo Tissue Slice Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Ex Vivo Tissue Slice Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Ex Vivo Tissue Slice Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Live Cell High Content Imaging Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Live Cell High Content Imaging Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Live Cell High Content Imaging Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Microfluidic Organ On Chip Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Microfluidic Organ On Chip Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Microfluidic Organ On Chip Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 95. Global Fully Custom Assay Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Fully Custom Assay Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Fully Custom Assay Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global GLP Compliant Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global GLP Compliant Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global GLP Compliant Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Integrated Discovery Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Integrated Discovery Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Integrated Discovery Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Project Based Contract Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Project Based Contract Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Project Based Contract Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Standardized Assay Panels Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Standardized Assay Panels Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Standardized Assay Panels Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Diagnostic And Companion Diagnostic Developers Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Diagnostic And Companion Diagnostic Developers Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Diagnostic And Companion Diagnostic Developers Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Hospitals And Clinical Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Hospitals And Clinical Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Hospitals And Clinical Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 130. Global Bispecifics And BiTEs Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Bispecifics And BiTEs Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Bispecifics And BiTEs Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Cell Therapies (CAR-T, TCR, CAR-NK) Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Cell Therapies (CAR-T, TCR, CAR-NK) Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Cell Therapies (CAR-T, TCR, CAR-NK) Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Checkpoint Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Checkpoint Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Checkpoint Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Vaccines And Immune Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Vaccines And Immune Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Vaccines And Immune Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 156. North America Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. North America Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 158. North America Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 159. North America Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 160. North America Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 161. North America Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 162. North America Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 163. North America Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 164. North America Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. North America Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 166. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 168. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 169. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 170. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 171. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 172. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 173. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 174. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Latin America Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 176. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 178. Europe Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 179. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 180. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 181. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 182. Europe Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 183. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 184. Europe Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Europe Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 186. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 188. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 189. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 190. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 191. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 192. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 193. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 194. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Middle East Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 196. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 198. Africa Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 199. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 200. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 201. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 202. Africa Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 203. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 204. Africa Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Africa Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 206. Global Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 208. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 209. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 210. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 211. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 212. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 213. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 214. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 215. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. ASEAN Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 217. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 219. GCC Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 220. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 221. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 222. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 223. GCC Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 224. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 225. GCC Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. GCC Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 227. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 229. European Union Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 230. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 231. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 232. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 233. European Union Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 234. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 235. European Union Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. European Union Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 237. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 238. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 239. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 240. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 241. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 242. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 243. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 244. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 245. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. BRICS Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 247. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 248. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 249. G7 Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 250. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 251. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 252. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 253. G7 Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 254. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 255. G7 Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. G7 Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 257. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 258. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 259. NATO Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 260. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 261. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 262. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 263. NATO Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 264. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 265. NATO Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. NATO Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 267. Global Immune Mediated Tumor Killing Assays Service Market Size, by Country, 2017-2032 (USD Million)
TABLE 268. United States Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
TABLE 269. United States Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 270. United States Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 271. United States Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 272. United States Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 273. United States Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 274. United States Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 275. United States Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 276. United States Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. United States Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 278. Canada Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
TABLE 279. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 280. Canada Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 281. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 282. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 283. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 284. Canada Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 285. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 286. Canada Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. Canada Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 288. Mexico Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
TABLE 289. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 290. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 291. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 292. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 293. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 294. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by 3D Co Culture Assays, 2017-2032 (USD Million)
TABLE 295. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Service Model, 2017-2032 (USD Million)
TABLE 296. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by End User, 2017-2032 (USD Million)
TABLE 297. Mexico Immune Mediated Tumor Killing Assays Service Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 298. Brazil Immune Mediated Tumor Killing Assays Service Market Size, 2017-2032 (USD Million)
TABLE 299. Brazil Immune Mediated Tumor Killing Assays Service Market Size, by Assay Type, 2017-2032 (USD Million)
TABLE 300. Brazil Immune Mediated Tumor Killing Assays Service Market Size, by CAR-T Cell Cytotoxicity, 2017-2032 (USD Million)
TABLE 301. Brazil Immune Mediated Tumor Killing Assays Service Market Size, by Detection Method, 2017-2032 (USD Million)
TABLE 302. Brazil Immune Mediated Tumor Killing Assays Service Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 303. Brazil Immune Mediated Tumor Killing Assays Service Market Size, by Assay Format, 2017-2032 (USD Million)
TABLE 304. Brazil Imm

Companies Mentioned

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BOC Sciences, Inc.
  • Charles River Laboratories, Inc.
  • Creative Biolabs, Inc.
  • Crown Bioscience, Inc.
  • EPO Berlin-Buch GmbH
  • Eurofins DiscoverX, LLC
  • Explicyte Immunology, Inc.
  • InnoSer B.V.
  • Nexus BioQuest LLC
  • Promega Corporation
  • Revvity, Inc.
  • Sartorius AG
  • WuXi AppTec Co., Ltd.

Related Reports

Advanced Methodologies to Study and Enhance Cellular Cytotoxicity Against Cancer. Methods in Cell Biology Volume 207 - Product Image

Advanced Methodologies to Study and Enhance Cellular Cytotoxicity Against Cancer. Methods in Cell Biology Volume 207

  • Book
NK Cell Cytotoxicity Assay Service Market - Global Forecast 2026-2032 - Product Image

NK Cell Cytotoxicity Assay Service Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
NK Cell Therapies - Pipeline Insight, 2025 - Product Image

NK Cell Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • 120 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2026 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
Bispecific Antibodies - Competitive Landscape, 2026 - Product Image

Bispecific Antibodies - Competitive Landscape, 2026

  • Report
  • 450 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.